Abstract | BACKGROUND: OBJECTIVE: This study investigated whether six-month high-dose, such as 300 IR (index of reactivity), HDM-sublingual immunotherapy (SLIT) could affect RI in allergic children. METHODS: Globally, 40 HDM allergic children (18 males; mean age, 9.3 years) were subdivided in 2 groups: 20 treated by symptomatic drugs (group 1) and 20 by high-dose HDM-SLIT (group 2), since September 2012 to April 2013. The daily maintenance dose of HDM-SLIT was 4 pressures corresponding to 24, 4.8, and 60 µg, respectively of the major allergens Dermatophagoides pteronyssinus ( Der p) 1, Der p 2, and Dermatophagoides farinae ( Der f) 1. RI was diagnosed when at least 2 symptoms or signs, and fever were present for at least 48 hours. A family pediatrician provided diagnosis on a clinical ground. RESULTS: SLIT-treated children had significantly (p = 0.01) less RI episodes (3.5) than control group (5.45). About secondary outcomes, SLIT-treated children had less episodes of pharyngo- tonsillitis (p < 0.05) and bronchitis (p < 0.005), and snoring (p < 0.05) than control group. In addition, SLIT-treated children had less fever (p < 0.01) and took fewer medications, such as antibiotics (p < 0.05) and fever-reducers (p < 0.01), than control group. CONCLUSION: This preliminary study might suggest that also a short course (6 months) of high-dose SLIT, titrated in µg of major allergens, could reduce RI in allergic children.
|
Authors | Salvatore Barberi, Giorgio Ciprandi, Elvira Verduci, Enza D'Auria, Piercarlo Poli, Benedetta Pietra, Cristoforo Incorvaia, Serena Buttafava, Franco Frati, Enrica Riva |
Journal | Asia Pacific allergy
(Asia Pac Allergy)
Vol. 5
Issue 3
Pg. 163-9
(Jul 2015)
ISSN: 2233-8276 [Print] Korea (South) |
PMID | 26240793
(Publication Type: Journal Article)
|